Roundtable Renal Cell Carcinoma
Sequencing, novel therapies, and treatment combinations for refractory RCC are examined in part 5 of this discussion. The panel explores the evolving role of cytoreductive nephrectomy in RCC and how biomarkers shape treatment decisions. The panel discusses considerations for triplet therapy in RCC, new trial data, and biomarker-driven treatment strategies. In part 2, the panelists discuss adjuvant therapy for RCC, including biomarkers and optimizing treatment for better outcomes. Part one of the discussion covers adjuvant therapy in kidney cancer, patient selection, and balancing risks and benefits. The panel concludes with the applications, challenges, and future prospects of belzutifan in treating advanced kidney cancer. The panel explores the latest research in rare subtypes of kidney cancer, emphasizing the need for biology-driven trials. The panel emphasizes the need to decrease RCC overtreatment and to identify cured patients in the adjuvant setting. The panel offers evolving strategies for managing treatment durations and holds for patients on IO/TKI and PD-1 regimens. The panel highlights the potential practice-changing impact of subcutaneous PD-1 agents for kidney cancer treatment.Dr. The panel focuses on the final OS analysis from the JAVELIN Renal 101 trial and the challenges of combining IOs with TKIs. The panel shared their excitement for the road ahead in kidney cancer. The panel addressed different dosing scenarios and shared tips on how to counsel patients on their treatment. The panel shared their thoughts on quality of life data presented from the LITESPARK-005 trial of belzutifan. The panel discussed the impact of a subcutaneous formulation of nivolumab. The panel discussed the role of SBRT and some exciting studies like SAMURAI. The panel discussed CheckMate 9ER, which assessed quality of life outcomes in patients receiving cabozantinib/nivolumab. The panel shared their thoughts on the 8-year follow-up data from CheckMate 214. The panel discussed two studies that assessed adjuvant treatment: KEYNOTE-564 and CheckMate 914. The panel forecasted some of the major questions that will be answered regarding belzutifan, triplet combinations, and more.